Ajax Therapeutics, Inc.

AltruBio Inc. took a big step up from its $63m series A venture capital round in 2021 when it announced a series B round totaling up to $225m on 21 May, which will fund ongoing and planned Phase IIa

Ajax Therapeutics, Inc. is going after an old target in myelofibrosis and other myeloproliferative neoplasms (MPNs) in a new way with its type II JAK2 inhibitor, AJ1-11095, which it will take into th

Venture capital firms focused on biopharmaceutical companies raised $810m across two new funds during the past two weeks, including $550m for venBio and Ysios Capital’s recently closed €216m ($260m) f

Presidents & CEOs Elan Corp. plc announces that by May 1, CEO Kelly Martin will “have successfully completed his commitment and overall duty as CEO to the company.” He has held the position since Ja